CN107373674A - Alimentation composition and its application after a kind of oncotherapy - Google Patents
Alimentation composition and its application after a kind of oncotherapy Download PDFInfo
- Publication number
- CN107373674A CN107373674A CN201710740919.8A CN201710740919A CN107373674A CN 107373674 A CN107373674 A CN 107373674A CN 201710740919 A CN201710740919 A CN 201710740919A CN 107373674 A CN107373674 A CN 107373674A
- Authority
- CN
- China
- Prior art keywords
- parts
- auxiliary material
- milk
- mixed
- powder
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 63
- 229920001542 oligosaccharide Polymers 0.000 claims abstract description 39
- 150000002482 oligosaccharides Chemical class 0.000 claims abstract description 39
- 239000000463 material Substances 0.000 claims abstract description 36
- 235000013793 astaxanthin Nutrition 0.000 claims abstract description 25
- 240000000759 Lepidium meyenii Species 0.000 claims abstract description 24
- 235000000421 Lepidium meyenii Nutrition 0.000 claims abstract description 24
- 235000012902 lepidium meyenii Nutrition 0.000 claims abstract description 24
- 239000000284 extract Substances 0.000 claims abstract description 23
- 235000020256 human milk Nutrition 0.000 claims abstract description 22
- 210000004251 human milk Anatomy 0.000 claims abstract description 22
- JEBFVOLFMLUKLF-IFPLVEIFSA-N Astaxanthin Natural products CC(=C/C=C/C(=C/C=C/C1=C(C)C(=O)C(O)CC1(C)C)/C)C=CC=C(/C)C=CC=C(/C)C=CC2=C(C)C(=O)C(O)CC2(C)C JEBFVOLFMLUKLF-IFPLVEIFSA-N 0.000 claims abstract description 15
- 239000001168 astaxanthin Substances 0.000 claims abstract description 15
- MQZIGYBFDRPAKN-ZWAPEEGVSA-N astaxanthin Chemical compound C([C@H](O)C(=O)C=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C(=O)[C@@H](O)CC1(C)C MQZIGYBFDRPAKN-ZWAPEEGVSA-N 0.000 claims abstract description 15
- 229940022405 astaxanthin Drugs 0.000 claims abstract description 15
- RQFQJYYMBWVMQG-IXDPLRRUSA-N chitotriose Chemical compound O[C@@H]1[C@@H](N)[C@H](O)O[C@H](CO)[C@H]1O[C@H]1[C@H](N)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)N)[C@@H](CO)O1 RQFQJYYMBWVMQG-IXDPLRRUSA-N 0.000 claims abstract description 12
- 239000000843 powder Substances 0.000 claims description 44
- 235000013305 food Nutrition 0.000 claims description 21
- 235000013336 milk Nutrition 0.000 claims description 21
- 239000008267 milk Substances 0.000 claims description 21
- 210000004080 milk Anatomy 0.000 claims description 21
- 239000003795 chemical substances by application Substances 0.000 claims description 18
- 206010028980 Neoplasm Diseases 0.000 claims description 16
- 238000000855 fermentation Methods 0.000 claims description 16
- 230000004151 fermentation Effects 0.000 claims description 16
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 14
- 235000016709 nutrition Nutrition 0.000 claims description 14
- 238000003756 stirring Methods 0.000 claims description 14
- 235000015140 cultured milk Nutrition 0.000 claims description 13
- 238000000034 method Methods 0.000 claims description 13
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 12
- 239000011259 mixed solution Substances 0.000 claims description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 11
- 239000000243 solution Substances 0.000 claims description 10
- 241000894006 Bacteria Species 0.000 claims description 9
- 239000000741 silica gel Substances 0.000 claims description 9
- 229910002027 silica gel Inorganic materials 0.000 claims description 9
- 230000001954 sterilising effect Effects 0.000 claims description 9
- 238000004659 sterilization and disinfection Methods 0.000 claims description 9
- 235000019890 Amylum Nutrition 0.000 claims description 8
- 229920002472 Starch Polymers 0.000 claims description 8
- 238000001816 cooling Methods 0.000 claims description 8
- 235000021552 granulated sugar Nutrition 0.000 claims description 8
- 229920002752 Konjac Polymers 0.000 claims description 7
- 235000013312 flour Nutrition 0.000 claims description 7
- 239000004310 lactic acid Substances 0.000 claims description 7
- 235000014655 lactic acid Nutrition 0.000 claims description 7
- 238000002156 mixing Methods 0.000 claims description 7
- 238000011049 filling Methods 0.000 claims description 5
- 238000011081 inoculation Methods 0.000 claims description 5
- 239000011812 mixed powder Substances 0.000 claims description 5
- 238000004806 packaging method and process Methods 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 4
- 210000000481 breast Anatomy 0.000 claims description 3
- 235000020247 cow milk Nutrition 0.000 claims description 3
- 238000003860 storage Methods 0.000 claims description 3
- 206010013911 Dysgeusia Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 abstract description 14
- 230000000694 effects Effects 0.000 abstract description 9
- 201000010099 disease Diseases 0.000 abstract description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 7
- 201000011510 cancer Diseases 0.000 abstract description 6
- 238000001959 radiotherapy Methods 0.000 abstract description 6
- 229940079593 drug Drugs 0.000 abstract description 3
- 230000003750 conditioning effect Effects 0.000 abstract description 2
- 230000007774 longterm Effects 0.000 abstract description 2
- 231100000957 no side effect Toxicity 0.000 abstract description 2
- 231100000331 toxic Toxicity 0.000 abstract description 2
- 230000002588 toxic effect Effects 0.000 abstract description 2
- 239000000047 product Substances 0.000 description 21
- 229920001661 Chitosan Polymers 0.000 description 12
- 150000001514 astaxanthins Chemical class 0.000 description 10
- 239000002994 raw material Substances 0.000 description 7
- 230000033228 biological regulation Effects 0.000 description 4
- 210000001035 gastrointestinal tract Anatomy 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 230000009471 action Effects 0.000 description 3
- 229920000615 alginic acid Polymers 0.000 description 3
- 235000010443 alginic acid Nutrition 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 150000004676 glycans Chemical class 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 235000008935 nutritious Nutrition 0.000 description 3
- 229920001282 polysaccharide Polymers 0.000 description 3
- 239000005017 polysaccharide Substances 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- 244000205754 Colocasia esculenta Species 0.000 description 2
- 235000006481 Colocasia esculenta Nutrition 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 125000004383 glucosinolate group Chemical group 0.000 description 2
- 235000012907 honey Nutrition 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- AEMOLEFTQBMNLQ-AZLKCVHYSA-N (2r,3s,4s,5s,6r)-3,4,5,6-tetrahydroxyoxane-2-carboxylic acid Chemical compound O[C@@H]1O[C@@H](C(O)=O)[C@@H](O)[C@H](O)[C@@H]1O AEMOLEFTQBMNLQ-AZLKCVHYSA-N 0.000 description 1
- YVWMHFYOIJMUMN-CYZWUHAYSA-N (6e,8e)-5-oxooctadeca-6,8-dienoic acid Chemical compound CCCCCCCCC\C=C\C=C\C(=O)CCCC(O)=O YVWMHFYOIJMUMN-CYZWUHAYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- 241000512259 Ascophyllum nodosum Species 0.000 description 1
- 241000972773 Aulopiformes Species 0.000 description 1
- 102000040350 B family Human genes 0.000 description 1
- 108091072128 B family Proteins 0.000 description 1
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 241000195493 Cryptophyta Species 0.000 description 1
- AEMOLEFTQBMNLQ-BZINKQHNSA-N D-Guluronic Acid Chemical compound OC1O[C@H](C(O)=O)[C@H](O)[C@@H](O)[C@H]1O AEMOLEFTQBMNLQ-BZINKQHNSA-N 0.000 description 1
- 241000238557 Decapoda Species 0.000 description 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000168517 Haematococcus lacustris Species 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 244000131316 Panax pseudoginseng Species 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 241000199919 Phaeophyceae Species 0.000 description 1
- 208000004403 Prostatic Hyperplasia Diseases 0.000 description 1
- 241000195474 Sargassum Species 0.000 description 1
- 241000222355 Trametes versicolor Species 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- LPQOADBMXVRBNX-UHFFFAOYSA-N ac1ldcw0 Chemical compound Cl.C1CN(C)CCN1C1=C(F)C=C2C(=O)C(C(O)=O)=CN3CCSC1=C32 LPQOADBMXVRBNX-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000001826 anti-prostatic effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- AEMOLEFTQBMNLQ-UHFFFAOYSA-N beta-D-galactopyranuronic acid Natural products OC1OC(C(O)=O)C(O)C(O)C1O AEMOLEFTQBMNLQ-UHFFFAOYSA-N 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 231100000357 carcinogen Toxicity 0.000 description 1
- 239000003183 carcinogenic agent Substances 0.000 description 1
- 235000021466 carotenoid Nutrition 0.000 description 1
- 150000001747 carotenoids Chemical class 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 208000033679 diabetic kidney disease Diseases 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- -1 flavouring Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 244000005709 gut microbiome Species 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000002434 immunopotentiative effect Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000013016 learning Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000002932 luster Substances 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 230000006386 memory function Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 230000001151 other effect Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000006041 probiotic Substances 0.000 description 1
- 235000018291 probiotics Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 235000019515 salmon Nutrition 0.000 description 1
- 230000036299 sexual function Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000008542 thermal sensitivity Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 238000009461 vacuum packaging Methods 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
- A23C9/13—Fermented milk preparations; Treatment using microorganisms or enzymes using additives
- A23C9/1307—Milk products or derivatives; Fruit or vegetable juices; Sugars, sugar alcohols, sweeteners; Oligosaccharides; Organic acids or salts thereof or acidifying agents; Flavours, dyes or pigments; Inert or aerosol gases; Carbonation methods
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C2240/00—Use or particular additives or ingredients
- A23C2240/15—Use of plant extracts, including purified and isolated derivatives thereof, as ingredient in dairy products
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Dairy Products (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses the alimentation composition after a kind of oncotherapy, including following component：In parts by weight, chitosan oligosaccharide is 100~1500 parts, and human milk oligosaccharides are 10~500 parts, and brown alga oligose is 200~3000 parts, and coriolan is 100~500 parts, and Maca extract is 50~2000 parts, and astaxanthin is 50~500 parts；100~9000 parts of auxiliary material.The present invention can be used for conditioning to receive radiotherapy or treat the condition of malignant tumor patient, strengthens healthy tendency, helps it to get well, and safety has no side effect.Said composition is different from medicine, and medicine all toxic side effects are long-term use of inevitably to produce " drug induced disease ", and take said composition and this problem is not present.
Description
Technical field
The invention belongs to technical field of health care food, is related to the alimentation composition after oncotherapy and its application.
Background technology
For malignant tumor patient after radiotherapy or treatment is received, it is impaired etc. to can frequently result in human body gas consumption impairment of yin, taste, so as to
Influence the circulation of qi and blood biochemistry.Now, by carrying out righting to human body, patient's body environment can be balanced, treatment toxicity is put in mitigation
Reaction；There are supplementing qi and nourishing yin, strengthening the spleen and stomach to radiotherapy：There is tonifying speen and tonifying kidney to treatment, relax liver and stomach.
Human body is referred to as healthy tendency by traditional Chinese medicine to the adaptability of external environment, resist ability and rehabilitation ability；And will be various
Pathogenic factor is referred to as perverse trend.Human righteousness is vigorous, and perverse trend should not invade, then health；If deficiency of vial QI, body disease-resistant defence
Inferior capabilities, then exopathogen follow, body is powerless to get rid of evils outgoing and falls ill.Therefore, search for the primary cause of disease in treatment, supplement healthy tendency and adjust and strengthen
The function of body is the basic principle of many diseases of Chinese traditional treatment.
Generally, bacterial micro-ecological balance of the healthy tendency of traditional Chinese medicine also with human body has close correlation, is especially to maintain
Microorganism species species in intestines and stomach, quantity, distribution are normal etc..Research shows, after malignant tumor patient receives radiotherapy or treatment,
One of the main reason for healthy tendency is deficient is to be particularly the unbalance of gut flora Tiny ecosystem in vivo." search for the primary cause of disease in treatment, supplement according to the traditional Chinese medical science
The principle of reatment of healthy tendency ", it is deficient to this healthy tendency, by adjusting internal Tiny ecosystem, the healthy tendency of body is lifted, is to improve such disease
One of effective means.
For the above-mentioned demand for receiving radiotherapy or treating malignant tumor patient, offer one kind is needed badly by adjusting bacterium in enteron aisle
The Tiny ecosystem of group, reach the oligosaccharide composition of righting qigong effect.
The content of the invention
Technical scheme provided by the invention is as follows：
The present invention provides the alimentation composition after a kind of oncotherapy, including following component：In parts by weight, chitosan oligosaccharide
For 10~500 parts, human milk oligosaccharides are 10~500 parts, and brown alga oligose is 200~3000 parts, and coriolan is 100~500 parts, agate
Coffee extract is 50~2000 parts, and astaxanthin is 50~500 parts；200~9000 parts of auxiliary material.
The present invention also provides a kind of application of alimentation composition, applied to being prepared into tumour non-whole nutritional formula food, milk
Powder, cultured milk.
The present invention also provides a kind of method that alimentation composition is prepared into tumour non-whole nutritional formula food, including following
Step：Crush：After taking chitosan oligosaccharide, brown alga oligose, coriolan, astaxanthin to be ground into fine powder, standby shell is formed after crossing 80 mesh sieves
Oligosaccharides powder, brown alga oligose powder, coriolan powder, astaxanthin powder；Dispensing：In a manner of equivalent progressively increases mixing, by human milk oligosaccharides, agate
Coffee extract, auxiliary material are well mixed with standby chitosan oligosaccharide powder, brown alga oligose powder, coriolan powder, astaxanthin powder to be made powdery and mixes
Compound；It is total mixed：After appropriate auxiliary material is added in the pulverulent mixture being mixed, total mixed 5 in three-dimensional motion mixer
~15min；Sieve, be filling：After pulverulent mixture after total mix is crossed into 24 mesh sieves, specification, is distributed into corresponding specification as desired
Finished product.
Further, the auxiliary material includes glidant, forming agent.
Further, the glidant includes superfine silica gel powder, and the forming agent includes konjaku flour.
The present invention also provides a kind of method that alimentation composition is prepared into milk powder, comprises the following steps：Dispensing：Take shell few
Sugar, human milk oligosaccharides, brown alga oligose, coriolan, Maca extract, astaxanthin, auxiliary material, after adding the pure water of 6-10 times of volume
Form mixed solution；Homogeneous：The mixed solution is poured into the tank body of high pressure homogenizer, homogeneous is carried out under 10~20MPa
30~45min；Dry：By the mixed solution after homogeneous EAT be 120~160 DEG C, feed rate be 10.50~
Under conditions of 14.50mL/min, it is spray-dried, obtains powder product；Packaging：Specification as desired, powder product is entered
Product of the row vacuum packaging into corresponding specification.
Further, the auxiliary material includes forming agent, flavouring.
Further, the forming agent includes amylum pregelatinisatum, and the flavouring includes white granulated sugar.
The present invention also provides a kind of method that alimentation composition is prepared into cultured milk, comprises the following steps：Primary batching system：
Chitosan oligosaccharide, human milk oligosaccharides, brown alga oligose, coriolan, Maca extract, astaxanthin are prepared into preliminary mixture；It is secondary to match somebody with somebody
Material：Stirred after adding auxiliary material in material-compound tank, add after appropriate auxiliary material and continue stirring and form mixed liquor；Preheating：Preheating
Temperature is that the mixed liquor is preheated at 60~65 DEG C；Homogeneous：Will preheating under 180~200bar using high pressure homogenizer
Mixed liquor afterwards carries out homogeneous；Sterilization：Continuous sterilization is carried out 300 seconds to the mixed liquor after homogeneous at being 92~98 DEG C in temperature；
Once cool down：Mixed liquor after sterilization is cooled to 41~43 DEG C of chilling temperature；Inoculation：Mixed liquor after cooling is poured into
Fermentation tank 1/3 when, add auxiliary material again, wait terminate feed after, stir 10~15 minutes；Fermentation：After stopping stirring, start to count
When ferment, by fermentation termination control in 70-75 ° of T；Secondary cooling, addition：Mixed liquor after fermentation is cooled to 18~22 DEG C
Afterwards, preliminary mixture is added；It is filling：Finished product is formed after squeezing into cultured milk basin, finished product was put in storage in 2 hours, and at 2~6 DEG C
It is lower to place more than 12 hours.
Further, second batch：Add in material-compound tank in the auxiliary material and stirred after milk solution, add appropriate institute
Flavouring in auxiliary material is stated, continues stirring after lactic acid bacteria and forms mixed liquor；Wherein, the milk solution is entered by pure water, cow's milk
Row is adjusted breast and made；Inoculation：When mixed liquor after cooling is poured into the 1/3 of fermentation tank, the lactic acid that adds again in the auxiliary material
Bacterium, after terminating to feed, stir 10~15 minutes.
Compared with prior art, the alimentation composition after a kind of oncotherapy provided by the invention and its application, have with
Lower beneficial effect：
1) alimentation composition in the present invention after oncotherapy, radiotherapy or treatment malignant tumor patient are received available for conditioning
Condition, strengthen healthy tendency, help it to get well, and safety have no side effect.Said composition is different from medicine, and medicine has
Toxic side effect, it is long-term use of inevitably to produce " drug induced disease ", and take said composition and this problem is not present.
The products taste of the present invention is good, makes simply, and nutritious, physiologically active ingredient content is high, has healthy dietotherapy concurrently
Effect, the health of people and quality of life can be improved as a kind of new formula food with healthcare function.
2) it is first that chitosan oligosaccharide, brown alga is few when 2) alimentation composition is prepared into tumour non-whole nutritional formula food by the present invention
Sugar, coriolan, astaxanthin crush, and add human milk oligosaccharides, Maca extract, auxiliary material；Component is carried out in batches according to valuable
Add, amount takes the mode of equal increments to add less；Always mixed purpose is to mix；After crossing 80 mesh so that component raw material is in granularity 80
Below mesh, it is easy to absorb；24 mesh are after preparation technology, and 24 mesh prevent middle caking or have debris, and simultaneous band is again
The effect of mixing.
3) no longer it is directly to crush when alimentation composition is prepared into milk powder by the present invention, and is formed into mixed solution, 10
Under~20MPa carry out 30~45min of homogeneous, EAT be 120~160 DEG C, feed rate be 10.50~14.50mL/
It is dried under conditions of min, its purpose make it that formed product and outward appearance are preferable.
4) when alimentation composition is prepared into cultured milk by the present invention, first preheated at 60~65 DEG C, under 180~200bar
Homogeneous, it is easy to so that component raw material is disperseed.
Embodiment
In order to illustrate more clearly about the embodiment of the present invention or technical scheme of the prior art, it is described below the present invention's
Embodiment.It should be evident that description is only some embodiments of the present invention below, for ordinary skill people
For member, on the premise of not paying creative work, other embodiments can also be obtained.
Embodiment 1
1st, each component raw material of the alimentation composition after oncotherapy：
In parts by weight, 100 parts of chitosan oligosaccharides are taken, 15 parts of human milk oligosaccharides, 2500 parts of brown alga oligoses, 130 parts of coriolans, 70
Part Maca extract, 110 parts of astaxanthins；30 parts of superfine silica gel powders, 70 portions of konjaku flours；The superfine silica gel powder is glidant, the evil spirit
Taro powder is forming agent；The glidant, forming agent are auxiliary material.
The 2nd, above-mentioned alimentation composition is prepared into the method for tumour non-whole nutritional formula food：
Crush：100 parts of chitosan oligosaccharides, 2500 parts of brown alga oligoses, 130 parts of coriolans, 110 parts of astaxanthins are ground into fine powder
Afterwards, standby mixed powder is formed after crossing 80 mesh sieves；
Dispensing：In a manner of equivalent progressively increases mixing, 15 parts of human milk oligosaccharides, 70 parts of Maca extracts are mixed with standby mixed powder
Uniformly pulverulent mixture is made in conjunction；
It is total mixed：After 30 parts of superfine silica gel powders, 70 portions of konjaku flours are added in the pulverulent mixture being mixed, in three maintenance and operations
5~15min is always mixed in dynamic mixer；
Sieve, be canned：After pulverulent mixture after total mix is crossed into 24 mesh sieves, specification, is distributed into corresponding specification as desired
Finished product.
3rd, a kind of application of alimentation composition, applied to being prepared into tumour non-whole nutritional formula food.
Instructions of taking：When taking, after dissolving tumour non-whole nutritional formula food with appropriate warm water, directly drink,
All operations are meeting《Special medicine purposes formula food Good Manufacture Practice》It is required that clean dried environment in carry out.
Embodiment 2
1st, each component raw material of the alimentation composition after oncotherapy：
In parts by weight, 800 parts of chitosan oligosaccharides are taken, 10 parts of human milk oligosaccharides, 1500 parts of brown alga oligoses, 500 parts of coriolans, 50
Part Maca extract, 500 parts of astaxanthins；35 parts of superfine silica gel powders, 65 portions of konjaku flours；The superfine silica gel powder is glidant, the evil spirit
Taro powder is forming agent；The glidant, konjaku flour are auxiliary material.
The 2nd, above-mentioned alimentation composition is prepared into the method for tumour non-whole nutritional formula food：
Crush：800 parts of chitosan oligosaccharides, 1500 parts of brown alga oligoses, 500 parts of coriolans, 500 parts of astaxanthins are ground into fine powder
Afterwards, standby mixed powder is formed after crossing 80 mesh sieves；
Dispensing：In a manner of equivalent progressively increases mixing, by 10 parts of human milk oligosaccharides, 50 parts of Maca extracts, superfine silica gel powder with it is standby
Pulverulent mixture is made with mixed powder is well mixed；
It is total mixed：After 35 parts of superfine silica gel powders, 65 portions of konjaku flours are added in the pulverulent mixture being mixed, in three maintenance and operations
5~15min is always mixed in dynamic mixer；
Sieve, be canned：After pulverulent mixture after total mix is crossed into 24 mesh sieves, specification, is distributed into corresponding specification as desired
Finished product.
3rd, a kind of application of alimentation composition, applied to being prepared into tumour non-whole nutritional formula food.
Instructions of taking：When taking, after dissolving tumour non-whole nutritional formula food with appropriate warm water, directly drink,
All operations are meeting《Special medicine purposes formula food Good Manufacture Practice》It is required that clean dried environment in carry out.
Embodiment 3
1st, each component raw material of the alimentation composition after oncotherapy：
In parts by weight, 1500 parts of chitosan oligosaccharides are taken, 300 parts of human milk oligosaccharides, 3000 parts of brown alga oligoses, 350 parts of coriolans,
1500 parts of Maca extracts, 50 parts of astaxanthins；250 parts of auxiliary materials；The auxiliary material includes forming agent, flavouring；The forming agent is adopted
With amylum pregelatinisatum, the flavouring uses white granulated sugar；The accounting of amylum pregelatinisatum and white granulated sugar is the 3%-10% of total amount.
The 2nd, above-mentioned alimentation composition is prepared into the method for milk powder：
Dispensing：Take 1500 parts of chitosan oligosaccharides, 300 parts of human milk oligosaccharides, 3000 parts of brown alga oligoses, 350 parts of coriolans, 1500 parts
Maca extract, 50 parts of astaxanthins, 250 parts of amylum pregelatinisatums and white granulated sugar, formation is mixed after adding the pure water of 6-10 times of volume
Close solution；
Homogeneous：The mixed solution is poured into the tank body of high pressure homogenizer, under 10~20MPa carry out homogeneous 30~
45min；
Dry：By the mixed solution after homogeneous EAT be 120~160 DEG C, feed rate be 10.50~
Under conditions of 14.50mL/min, it is spray-dried, obtains powder product；
Packaging：Specification as desired, powder product is vacuum-packed into the product of corresponding specification.
3rd, a kind of application of alimentation composition, applied to being prepared into milk powder.
Instructions of taking：When taking, after dissolving milk powder with appropriate warm water, directly drink, all operations are meeting
《Special medicine purposes formula food Good Manufacture Practice》It is required that clean dried environment in carry out.
Embodiment 4
1st, each component raw material of the alimentation composition after oncotherapy：
In parts by weight, 500 parts of chitosan oligosaccharides are taken, 500 parts of human milk oligosaccharides, 200 parts of brown alga oligoses, 100 parts of coriolans,
2000 parts of Maca extracts, 500 parts of astaxanthins；250 parts of auxiliary materials；The auxiliary material includes forming agent, flavouring；The forming agent is adopted
With amylum pregelatinisatum, the flavouring uses white granulated sugar；Amylum pregelatinisatum or with 3%-10% that the accounting of white granulated sugar is total amount.
The 2nd, above-mentioned alimentation composition is prepared into the method for milk powder：
Dispensing：Take 500 parts of chitosan oligosaccharides, 500 parts of human milk oligosaccharides, 200 parts of brown alga oligoses, 100 parts of coriolans, 2000 parts of agates
Coffee extract, 500 parts of astaxanthins, 250 parts of amylum pregelatinisatums and white granulated sugar, mixing is formed after adding the pure water of 6-10 times of volume
Solution；
Homogeneous：The mixed solution is poured into the tank body of high pressure homogenizer, under 10~20MPa carry out homogeneous 30~
45min；
Dry：By the mixed solution after homogeneous EAT be 120~160 DEG C, feed rate be 10.50~
Under conditions of 14.50mL/min, it is spray-dried, obtains powder product；
Packaging：Specification as desired, powder product is vacuum-packed into the product of corresponding specification.
3rd, a kind of application of alimentation composition, applied to being prepared into milk powder.
Instructions of taking：When taking, after dissolving milk powder with appropriate warm water, directly drink, all operations are meeting
《Special medicine purposes formula food Good Manufacture Practice》It is required that clean dried environment in carry out.
Embodiment 5
1st, each component raw material of the alimentation composition after oncotherapy：
In parts by weight, 110 parts of chitosan oligosaccharides are taken, 20 parts of human milk oligosaccharides, 800 parts of brown alga oligoses, 150 parts of coriolans, 100
Part Maca extract, 200 parts of astaxanthins；8620 parts of auxiliary materials；The auxiliary material includes milk solution, flavouring, lactic acid bacteria；It is described to rectify
Taste agent includes honey element, pectin.
The 2nd, above-mentioned alimentation composition is prepared into the method for cultured milk：
Primary batching system：By 110 parts of oligosaccharides, 20 parts of human milk oligosaccharides, 800 parts of brown alga oligoses, 150 parts of coriolans, 100 parts of agates
Coffee extract, 200 parts of astaxanthins are prepared into preliminary mixture；
Second batch：In material-compound tank add 8500 parts of milk solutions after stir, add 40 parts honey element, 20 portions of fruits
Continue stirring after glue, 30 parts of lactic acid bacterias and form mixed liquor；Wherein, the milk solution by pure water, cow's milk carry out adjust breast and
System；
Preheating：The mixed liquor is preheated at being 60~65 DEG C in preheating temperature；
Homogeneous：The mixed liquor after preheating is subjected to homogeneous under 180~200bar using high pressure homogenizer；
Sterilization：Continuous sterilization is carried out 300 seconds to the mixed liquor after homogeneous at being 92~98 DEG C in temperature；
Once cool down：Mixed liquor after sterilization is cooled to 41~43 DEG C of chilling temperature；
Inoculation：When mixed liquor after cooling is poured into the 1/3 of fermentation tank, 30 parts of lactic acid bacterias are added again, are entered to the end of
After material, stir 10~15 minutes；
Fermentation：After stopping stirring, start timing fermentation, fermentation termination is controlled in 70-75 ° of T；
Secondary cooling, addition：After mixed liquor after fermentation is cooled into 18~22 DEG C, preliminary mixture is added；
It is filling：Finished product is formed after squeezing into cultured milk basin, finished product was put in storage in 2 hours, and placement 12 is small at 2~6 DEG C
When more than.
3rd, a kind of application of alimentation composition, applied to being prepared into cultured milk.Instructions of taking：After opening basin, directly drink
With；Cultured milk has simultaneously promotes the nutritional ingredient recovered after tumor operation, nutritious, mouthfeel is novel.
It should be noted that：Except the alimentation composition after oncotherapy is prepared into the non-full nutrient formulation food of tumour
Product, milk powder, outside cultured milk, the alimentation composition after oncotherapy can also be prepared into solid beverage etc..
In the above-described embodiments, chitosan oligosaccharide (Chtiosnaoligosaccharide, COS), it is called Chitosan poly oligosaccharide, oligomeric
Chitosan, it is a kind of degree of polymerization for obtaining chitosan through special bio-enzyme degradation oligosaccharide product, molecular weight between 2~20
≤ 3200Da, water-soluble preferable, easy absorption, low molecular weight product degradable, bioactivity is high.Chitosan oligosaccharide has regulation dynamic
The metabolic activity of microorganism in thing enteron aisle, improve intestinal microflora distribution, promote bifid bar mattress growth and breeding, so as to improve
Immunity of organisms, decline pH in enteron aisle, suppress harmful intestinal tract bacteria growing, produce B family vitamin, decompose carcinogen, promote
Enterocinesia, promote protein adsorption and other effects.It is widely used in food and field of medicaments.
Human milk oligosaccharides (HMO) are the oligosaccharide that the one kind being present in natural breast milk is made up of 2-10 monose, are generally acknowledged
There is the natural molecule of very high potentiality in nutrition and biomedical applications field.Available for improvement baby, child, Er Tonghuo
The digestive tract function of adult and the alimentation composition of immunity, the immune of baby is mainly influenceed by the influence to flora indirectly
System, growth and the maturation of alimentary canal barrier, regulation gut flora, the growth for being advantageous to probiotics, defence breathing system can be improved
The infection of system and urinary system, regulation immune system improve immunity of organisms and Subhealth treating.
Brown alga oligose (Alginateoligosaccharides), also known as algin oligosaccharide, it is by degrading by algin
Obtained oligomer.The brown algae plant such as sea-tangle, sargassum, bulk kelp is mostly come from, there is antitumor, enhancing to be immunized, growth-promoting
A variety of physiologically actives such as long.
Algae oligosaccharides is the oligomer of algin, is a kind of functional oligosaccharide.Brown alga oligose is by β-D mannuronic acids (ManA)
It is formed by connecting with its C-5 epimer α-L guluronic acid (GulA) by 1-4 glycosidic bonds.Brown alga oligose molecular weight is low, no
Only water-soluble strong, stability is high, and has many bioactivity, such as antitumor, anti-oxidant, antibacterial, growth promotion.
Coriolan (PSK), it is a kind of active polysaccharide extracted from prepared from coriolus versicolor mycelium or rainbow conk nutrient solution, has a variety of
Bioactivity, it is internationally recognized efficient immunopotentiating agent.Cancer metastasis can be not only resisted, immunological regulation can also be promoted
Effect, and learning and memory function can be effectively improved, it is a kind of polysaccharide of good protection organism physiological function.
Maca (Lepidium meyenii), also known as agate card, Peru's ginseng etc. are more containing maca ene, macamide, maca
The multiple components such as sugar, glucosinolate and its derivative, it is nutritious, there is dispelling fatigue, compressive resistance, improve immune, alleviation more
Term syndrome, anti-prostatic hyperplasia, improve the physiological actions such as sexual function.Research shows that maca is recovered to sub-health state crowd
Health has good corrective action.But due to some functional components in maca, such as polysaccharide, glucosinolate, alkaloid,
Structure can be destroyed under long-time high temperature action, lose effect, and normal temperature extraction time is very long, recovery rate is low, causes resource unrestrained
Take, and the both effectiveness existing water-soluble components of maca, also there are lipid soluble ingredients, single solvent extracts not exclusively to effective component,
Cause the wasting of resources, therefore, Maca extract used in the present invention, using the concentration of ultrasound-enhanced normal temperature rapid extraction-low temperature and
Dry and be made, it is therefore prevented that thermal sensitivity effective component activity is destroyed, and obtained high activity Maca extract.
Astaxanthin (Astaxanthin) is a kind of former carotenoid of non-vitamin A, be primarily present in haematococcus pluvialis,
In the biology such as shrimp, crab, salmon.As a kind of natural pigment, astaxanthin is safe and non-toxic, aboundresources, bright in luster.With anti-
The bioactivity such as oxidation, prevention of cardiovascular disease and diabetic nephropathy, are a kind of potential resource medicines.
It should be noted that above-described embodiment can independent assortment as needed.Described above is only the preferred of the present invention
Embodiment, it is noted that for those skilled in the art, do not departing from the premise of the principle of the invention
Under, some improvements and modifications can also be made, these improvements and modifications also should be regarded as protection scope of the present invention.
Claims (10)
1. the alimentation composition after a kind of oncotherapy, it is characterised in that including following component：
In parts by weight, chitosan oligosaccharide is 100~1500 parts, and human milk oligosaccharides are 10~500 parts, and brown alga oligose is 200~3000 parts,
Coriolan is 100~500 parts, and Maca extract is 50~2000 parts, and astaxanthin is 50~500 parts；Auxiliary material 100~9000
Part.
A kind of 2. application of alimentation composition as claimed in claim 1, it is characterised in that：Applied to being prepared into, tumour is non-to seek entirely
Support formula food, milk powder, cultured milk.
3. a kind of method that alimentation composition as claimed in claim 1 is prepared into tumour non-whole nutritional formula food, it is special
Sign is, comprises the following steps：
Crush：After taking chitosan oligosaccharide, brown alga oligose, coriolan, astaxanthin to be ground into fine powder, standby mixing is formed after crossing 80 mesh sieves
Powder；
Dispensing：In a manner of equivalent progressively increases mixing, human milk oligosaccharides, Maca extract, auxiliary material are well mixed with standby mixed powder
Pulverulent mixture is made；
It is total mixed：After appropriate auxiliary material is added in the pulverulent mixture being mixed, total mixed 5 in three-dimensional motion mixer~
15min；
Sieve, be filling：Will it is total mixed after pulverulent mixture cross 24 mesh sieves after, specification as desired, be distributed into corresponding specification into
Product.
4. the preparation method of tumour non-whole nutritional formula food as claimed in claim 3, it is characterised in that：The auxiliary material includes
Glidant, forming agent.
5. the preparation method of tumour non-whole nutritional formula food as claimed in claim 4, it is characterised in that：The glidant bag
Superfine silica gel powder is included, the forming agent includes konjaku flour.
A kind of 6. method that alimentation composition as claimed in claim 1 is prepared into milk powder, it is characterised in that including following step
Suddenly：
Dispensing：Chitosan oligosaccharide, human milk oligosaccharides, brown alga oligose, coriolan, Maca extract, astaxanthin, auxiliary material are taken, adds 6-10
Mixed solution is formed after the pure water of times volume；
Homogeneous：The mixed solution is poured into the tank body of high pressure homogenizer, 30~45min of homogeneous is carried out under 10~20MPa；
Dry：By the mixed solution after homogeneous EAT be 120~160 DEG C, feed rate be 10.50~14.50mL/
Under conditions of min, it is spray-dried, obtains powder product；
Packaging：Specification as desired, powder product is vacuum-packed into the product of corresponding specification.
7. method for preparing milk as claimed in claim 6, it is characterised in that：The auxiliary material includes forming agent, flavouring.
8. method for preparing milk as claimed in claim 7, it is characterised in that：The forming agent includes amylum pregelatinisatum, described
Flavouring includes white granulated sugar.
A kind of 9. method that alimentation composition as claimed in claim 1 is prepared into cultured milk, it is characterised in that including following
Step：
Primary batching system：Chitosan oligosaccharide, human milk oligosaccharides, brown alga oligose, coriolan, Maca extract, astaxanthin are prepared into standby
Mixture；
Second batch：Stirred after adding auxiliary material in material-compound tank, add after appropriate auxiliary material and continue stirring and form mixed liquor；
Preheating：The mixed liquor is preheated at being 60~65 DEG C in preheating temperature；
Homogeneous：The mixed liquor after preheating is subjected to homogeneous under 180~200bar using high pressure homogenizer；
Sterilization：Continuous sterilization is carried out 300 seconds to the mixed liquor after homogeneous at being 92~98 DEG C in temperature；
Once cool down：Mixed liquor after sterilization is cooled to 41~43 DEG C of chilling temperature；
Inoculation：When mixed liquor after cooling is poured into the 1/3 of fermentation tank, auxiliary material is added again, after terminating to feed, stirring 10
~15 minutes；
Fermentation：After stopping stirring, start timing fermentation, fermentation termination is controlled in 70-75 ° of T；
Secondary cooling, addition：After mixed liquor after fermentation is cooled into 18~22 DEG C, preliminary mixture is added；
It is filling：Form finished product after squeezing into cultured milk basin, finished product was put in storage in 2 hours, and place at 2~6 DEG C 12 hours with
On.
10. cultured milk preparation method as claimed in claim 9, it is characterised in that：
Second batch：Add in material-compound tank in the auxiliary material and stirred after milk solution, add in the appropriate auxiliary material and rectify
Continue stirring after taste agent, lactic acid bacteria and form mixed liquor；Wherein, the milk solution carries out adjusting breast to make by pure water, cow's milk；
Inoculation：When mixed liquor after cooling is poured into the 1/3 of fermentation tank, the lactic acid bacteria that adds again in the auxiliary material waits to tie
After beam charging, stir 10~15 minutes.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710740919.8A CN107373674A (en) | 2017-08-25 | 2017-08-25 | Alimentation composition and its application after a kind of oncotherapy |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710740919.8A CN107373674A (en) | 2017-08-25 | 2017-08-25 | Alimentation composition and its application after a kind of oncotherapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN107373674A true CN107373674A (en) | 2017-11-24 |
Family
ID=60346687
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710740919.8A Pending CN107373674A (en) | 2017-08-25 | 2017-08-25 | Alimentation composition and its application after a kind of oncotherapy |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107373674A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113925166A (en) * | 2020-12-14 | 2022-01-14 | 常州市第二人民医院 | Astaxanthin composition and preparation method thereof |
| CN113975383A (en) * | 2021-10-14 | 2022-01-28 | 广东渔跃生物技术有限公司 | Rhodococcus ruber immunopotentiator and application thereof in swine vaccine |
Citations (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1506067A (en) * | 2002-12-06 | 2004-06-23 | 中国科学院大连化学物理研究所 | Application of chitin oligose in anticancer drug |
| CN101653283A (en) * | 2009-09-10 | 2010-02-24 | 张树文 | Chitosan oligosaccharide drinking water |
| CN102258563A (en) * | 2010-05-28 | 2011-11-30 | 浦元清 | Anti-cancer medicinal composition and Chinese medicinal composition |
| CN102497869A (en) * | 2009-07-15 | 2012-06-13 | N.V.努特里奇亚 | Fucosyllactose as breast milk identical non-digestible oligosaccharide with new functional benefit |
| CN102497868A (en) * | 2009-07-15 | 2012-06-13 | N.V.努特里奇亚 | Mixture of non-digestible oligosaccharides for stimulating the immune system |
| CN102946742A (en) * | 2010-04-27 | 2013-02-27 | N·V·努特里奇亚 | Use of human milk oligosaccharides in infant nutrition |
| CN103379908A (en) * | 2010-12-31 | 2013-10-30 | 雅培制药有限公司 | Methods for reducing the incidence of oxidative stress using human milk oligosaccharides, vitamin c and anti-inflammatory agents |
| CN103404765A (en) * | 2013-08-29 | 2013-11-27 | 青岛海百合生物技术有限公司 | Composite marine special dietary food for consumption of tumor patients |
| CN103565817A (en) * | 2013-11-11 | 2014-02-12 | 深圳大学 | Application of alginate oligosaccharide |
| CN104664387A (en) * | 2015-03-19 | 2015-06-03 | 沈阳伊人宝生化制品有限公司 | Lepidium meyenii walp Yiren |
| CN104824513A (en) * | 2015-05-26 | 2015-08-12 | 云南和融生物科技有限公司 | Maca moringa oleifera tablets and preparation method thereof |
| CN106306921A (en) * | 2016-08-22 | 2017-01-11 | 青岛三九九洲生物技术有限公司 | Method for preparing chitosan oligosaccharide functional beverage with Maca and Cordyceps sinensis and functional beverage made thereby |
| CN106344595A (en) * | 2015-07-17 | 2017-01-25 | 上海绿谷制药有限公司 | Application of sodium alginate oligose and derivative to treatment of pain |
| CN106879817A (en) * | 2017-03-05 | 2017-06-23 | 山东陆海蓝圣生物科技股份有限公司 | Xylitol maca pressed candy factory formula and its production technology |
-
2017
- 2017-08-25 CN CN201710740919.8A patent/CN107373674A/en active Pending
Patent Citations (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1506067A (en) * | 2002-12-06 | 2004-06-23 | 中国科学院大连化学物理研究所 | Application of chitin oligose in anticancer drug |
| CN102497869A (en) * | 2009-07-15 | 2012-06-13 | N.V.努特里奇亚 | Fucosyllactose as breast milk identical non-digestible oligosaccharide with new functional benefit |
| CN102497868A (en) * | 2009-07-15 | 2012-06-13 | N.V.努特里奇亚 | Mixture of non-digestible oligosaccharides for stimulating the immune system |
| CN101653283A (en) * | 2009-09-10 | 2010-02-24 | 张树文 | Chitosan oligosaccharide drinking water |
| CN102946742A (en) * | 2010-04-27 | 2013-02-27 | N·V·努特里奇亚 | Use of human milk oligosaccharides in infant nutrition |
| CN102258563A (en) * | 2010-05-28 | 2011-11-30 | 浦元清 | Anti-cancer medicinal composition and Chinese medicinal composition |
| CN103379908A (en) * | 2010-12-31 | 2013-10-30 | 雅培制药有限公司 | Methods for reducing the incidence of oxidative stress using human milk oligosaccharides, vitamin c and anti-inflammatory agents |
| CN103404765A (en) * | 2013-08-29 | 2013-11-27 | 青岛海百合生物技术有限公司 | Composite marine special dietary food for consumption of tumor patients |
| CN103565817A (en) * | 2013-11-11 | 2014-02-12 | 深圳大学 | Application of alginate oligosaccharide |
| CN104664387A (en) * | 2015-03-19 | 2015-06-03 | 沈阳伊人宝生化制品有限公司 | Lepidium meyenii walp Yiren |
| CN104824513A (en) * | 2015-05-26 | 2015-08-12 | 云南和融生物科技有限公司 | Maca moringa oleifera tablets and preparation method thereof |
| CN106344595A (en) * | 2015-07-17 | 2017-01-25 | 上海绿谷制药有限公司 | Application of sodium alginate oligose and derivative to treatment of pain |
| CN106306921A (en) * | 2016-08-22 | 2017-01-11 | 青岛三九九洲生物技术有限公司 | Method for preparing chitosan oligosaccharide functional beverage with Maca and Cordyceps sinensis and functional beverage made thereby |
| CN106879817A (en) * | 2017-03-05 | 2017-06-23 | 山东陆海蓝圣生物科技股份有限公司 | Xylitol maca pressed candy factory formula and its production technology |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113925166A (en) * | 2020-12-14 | 2022-01-14 | 常州市第二人民医院 | Astaxanthin composition and preparation method thereof |
| CN113975383A (en) * | 2021-10-14 | 2022-01-28 | 广东渔跃生物技术有限公司 | Rhodococcus ruber immunopotentiator and application thereof in swine vaccine |
| CN113975383B (en) * | 2021-10-14 | 2023-10-20 | 广东渔跃生物技术有限公司 | Rhodococcus erythropolis immunopotentiator and application thereof in vaccine for pigs |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN107751387A (en) | A kind of formula milk and its production method for helping to reduce blood sugar for human body | |
| CN103110861B (en) | Granular preparation for preventing infants from getting inflamed and adjusting intestines and stomach and preparation method thereof | |
| CN100512667C (en) | Pig feed addictive | |
| KR101539382B1 (en) | Food composition for improvement of bowel function and relief of constipation | |
| CN113412862A (en) | Formula milk powder for middle-aged and old people and preparation method thereof | |
| CN102994346A (en) | Base stock for preparing MACA wine | |
| CN106490360A (en) | One boar green feed additive and preparation method thereof | |
| CN107173656A (en) | A kind of Chinese medicine fruits and vegetables probiotics fermented beverage and preparation method thereof | |
| CN109007224A (en) | A kind of pressed candy and preparation method thereof containing Astaxanthin In Haematococcus Pluvialis conditioning female organism | |
| CN106993788A (en) | All Pure Nature royal jelly lozenge and preparation method thereof | |
| CN106616602A (en) | Preparation method of black Chinese wolfberry fruit probiotic tablets | |
| CN107373674A (en) | Alimentation composition and its application after a kind of oncotherapy | |
| CN107319550A (en) | Brain trauma full nutrition formula food | |
| CN106070813A (en) | Green tea powder nourishing medicinal granule | |
| CN112425655A (en) | Formula milk powder for preventing hyperlipidemia, hyperglycemia and hypertension and preparation method thereof | |
| CN107751880A (en) | A kind of dust composition and preparation method of the improvement enteric microorganism containing prebiotics | |
| CN107136513A (en) | Adjust the health food of colony balance, preparation method and applications in human body | |
| CN106923342A (en) | A kind of selenium-rich passion fruit amino acid lozenge and preparation method thereof | |
| JP2002209553A (en) | Carcinostatic healthy food and additive for healthy food | |
| CN105661212A (en) | Corn and tremella clear juice beverage and preparation method thereof | |
| CN103271353B (en) | Liver protecting and health care composition and preparation method thereof | |
| CN115486541B (en) | Herbal probiotic composition with whitening effect and preparation method thereof | |
| CN105495621A (en) | Health-care food used for protecting liver and stomach and preparation method thereof | |
| CN108936183A (en) | A kind of compound endothelium corneum gigeriae galli solid beverage | |
| CN107095112A (en) | A kind of beverage containing resveratrol and chitosan oligosaccharide |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20171124 |